16S rRNA gene sequencing of stool samples collected from patients with latent tuberculosis infection before, during, and two months after treatment with 3HP or 4R

Objective: We present 16s rRNA gene sequencing (V1-V2 region) and sample data from a pilot observational cohort study to describe the gut microbiota dynamics in patients with latent tuberculosis infection (LTBI) treated with a three to four-month course of a rifamycin-based regimen. Our objectives were to (1) document changes to the gut microbiota following exposure to the rifamycins and (2) document recovery to baseline two months after treatment completion. Data description Six LTBI patients were followed for 5 – 6 months. Each patient provided stool samples before, during, and two months after treatment. Six healthy controls were sampled in parallel with the LTBI patients. We report amplicon sequence variants (ASVs) and taxonomic assignments for 60 stool samples. Also provided are the raw amplicon sequences, and data on diet, medication, and lifestyle changes over the follow-up period. Additionally, phosphate buffer washes of the stool samples from the LTBI participants were analyzed by validated LC-MS-MS assay to measure concentrations of the parent and partially active metabolite rifamycins. These data could be useful for future systematic reviews and meta-analyses on the impact of LTBI therapy on the gut microbiota.